arrow
M

Meta Roestenberg

leiden university medical center
H指数:41
被引数:6,740

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Heritable transgenic schistosomes as a living platform for SARS-CoV-2 neutralizing antibody secretion

可遗传转基因血吸虫作为SARS-CoV-2中和抗体分泌的活体平台

2026-08-260
OA
Temporal modulation of gene expression in a controlled Schistosoma mansoni human infection model

在受控的Schistosoma mansoni人体感染模型中基因表达的时序调控

2025-12-160
OAAI
Intradermal immunization with Plasmodium berghei late-arresting genetically attenuated sporozoites induces PD-L1 expression on regulatory macrophages and dendritic cells

皮内注射伯氏疟原虫晚期阻断的遗传减毒子孢子诱导调节性巨噬细胞和树突状细胞表达PD-L1

2025-12-120
OAAI
Manufacture of Clostridioides difficile Spores for Experimental Infection of Human Volunteers

艰难梭菌孢子(Clostridioides difficile Spores)的制备用于人体志愿者的实验性感染

2025-12-010
OAAI
T cell responses in repeated controlled human schistosome infection compared to natural exposure

Driciru, E.; Koopman, J.P.R.; Steenbergen, S.; Sonnet, F.; Stam, K.A.; Bes-Roeleveld, L.; Iliopoulou, E.; Janse, J.J.; Sijtsma, J.; Nambuya, I.; et al. T细胞反应在重复控制的类人血吸虫感染与自然暴露的比较。Nat. Commun. 2025, 16, 6827. [Google Scholar] [CrossRef]

2025-07-240
OAAI
How to develop a controlled human infection model for Clostridioides difficile

如何开发用于艰难梭菌(Clostridioides difficile)的受控人类感染模型

2025-03-011
OAAI
Identification of a circulating carbohydrate antigen as a highly specific and sensitive target for schistosomiasis serology
2025-02-190
OAAI
Safety, Tolerability, and Immunogenicity of the InvaplexAR-Detox Shigella Vaccine Co-Administered with the dmLT Adjuvant in Dutch and Zambian Adults: Study Protocol for a Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase Ia/b Clinical Trial
2025-01-080
OAAI
Safety and Efficacy of Immunization with a Late-Liver-Stage Attenuated Malaria Parasite
2024-11-210
PRE
Vaccine value profile for schistosomiasis

血吸虫病疫苗价值概要

Vaccine
IF3.5
2024-07-230
OAAI
No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials
2024-03-312
OAAI
Intradermal delivery of the third dose of the mRNA-1273 SARS-CoV-2 vaccine: safety and immunogenicity of a fractional booster dose

第三剂mRNA-1273 SARS-CoV-2疫苗的皮内递送: 部分加强剂量的安全性和免疫原性

2024-03-010
OA
Immunogenicity and reactogenicity of intradermal mRNA-1273 SARS-CoV-2 vaccination: a non-inferiority, randomized-controlled trial
2024-01-025
OAAI